Information to consider regarding whether or not you will get the Flu Vaccine
Here are a partial list of cases that were awarded damages by the US Government via the “Vaccine Court”, which is a federal court of claims for the FLU VACCINE: Vaccine Program/Office of Special Masters | US Court of Federal …
“All vaccine claims are managed and adjudicated by the congressionally-created Office of Special Masters…”
Many of these decisions include the stipulation that the Respondent (the government) denies injury/death was caused-in-fact by vaccination, nonetheless, the parties agreed informally to resolve this matter …
Vaccine Program/Office of Special Masters | US Court of Federal …
Stipulation; trivalent influenza vaccine ; Guillain-Barre Syndrome DARRYL ALDRICH, August 31, 2012
Damages Decision Based on Stipulation; Flu Vaccine ; GBS RAY SIZEMORE, August 27, 2012
Stipulation; Influenza ; Neuropathy; Myelopathy H.G. 08/27/2012
Stipulation; Influenza vaccine; Acute demyelinating encephalomyelitis PAMELA A. GOUDGE, as Parent and Legal Representative of her Minor Daughter, MEGAN ELIZABETH GOUDGE 08/17/2012
Decision by Stipulation; Influenza Vaccine ; Encephalopathy, ADEM, Brain Lesions LEE HAMES 08/16/2012
Decision by Stipulation; Influenza Vaccine ; Guillain-Barre Syndrome (GBS); CIDP DEBORAH E. BRADLEY 08/16/2012
Damages Decision Based on Stipulation; Miller Fisher Variant of GBS; Flu Vaccine .TERRIE EAST 08/01/2012
Joint Stipulation on Damages; Trivalent Influenza (揊lu? Vaccine ; Guillain-Barré Syndrome (揋BS?.DESSA STABOLESKI 07/31/2012
Stipulation; Influenza vaccine ; Acute demyelinating encephalomyelitis Stipulation; Trivalent influenza vaccine, flu; Guillain-Barré Syndrome, GBS THERESA LYNCH 07/24/2012
Influenza vaccine , flu; Guillain-Barré Syndrome, GBS; Stipulation RICHARD D. HUMMEL 07/24/2012
Damages Decision Based on Stipulation; Flu Vaccine ; Encephalomyeloneuropathy LAURA LARUE 07/12/2012
Damages Decision Based on Stipulation; Flu Vaccine ; Allergic Reaction; Progressive URI DWIGHT MUNGER 07/12/2012
Stipulation; Influenza vaccine; generalized itching. PATRICIA MORROW 07/11/2012
Stipulation; Influenza; CIDP JAMES JIM KINDELL 07/09/2012
Stipulation; influenza vaccine ; Guillain-Barre syndrome. MONA MENKING 07/09/2012
Stipulation; influenza vaccine; Guillain-Barre Syndrome DANIEL IRWIN 07/06/2012
Stipulation; influenza (flu) vaccine ; transverse myelitis (TM) ARTHUR W. ASKEW 06/29/2012
Stipulation; Influenza vaccine, flu ; Ventricular fibrillation and cardiac arrest PAUL L. CLEARY 06/28/2012
Stipulation; influenza (flu) vaccine ; Guillain-Barre Syndrome (GBS) THOMAS KIEF 06/28/2012
Stipulation; influenza (flu) vaccine ; neurological abnormalities; transverse myelitis (TM) LISA BURRELL 06/28/2012
Stipulation; influenza vaccine ; transverse myelitis CAROL LYNNE GOERNER 06/25/2012
Stipulation; trivalent influenza vaccine; acute hearing loss; vertigo. JOSEPH MAUS 06/22/2012
Stipulation; Influenza vaccine , flu; Transverse myelitis, TM RICHARD PETRAGLIA 06/01/2012
Ruling on the record; trivalent (flu) vaccine ; acute disseminated encephalomyelitis (揂DEM? JESSICA MURA (healthy 21-year old Emergency Medical Technician) 05/30/2012
Stipulation; Influenza vaccine, flu; Rhomboencephalitis; Dysautonomia; Attorney fees and costs JAY D. PRIEFERT 05/18/2012
Damages Decision Based on Stipulation; Flu Vaccine; GBS; Death Estate of DRAGO POTOCIC, 05/15/2012
Stipulation; Influenza ; GBS PAMELA KWIATKOWSKI 05/15/2012
Damages Decision Based on Stipulation; Flu Vaccine; GBS; Death Estate of DEBORA KAY STEELEY, 05/08/2012
Stipulation; Influenza; GBS GARY C. STEBNITZ 05/01/2012
Stipulation; Influenza; GBS CRYSTAL L. RHODES 04/26/2012
Stipulation; CIDP; influenza DENIS LOUIS 04/18/2012
Damages Decision Based on Stipulation; Flu Vaccine ; GBS; Attorneys?Fees & Costs Decision Based on Stipulation MARY L. JONES 04/18/2012
Stipulation; influenza (flu) vaccine ; Guillain-Barre Syndrome (GBS) ELIZABETH JASNOSZ 04/16/2012
Decision on the Record; Urticarial Vasculitis; Influenza AUDREY MCELROY 04/13/2012
Stipulation; Influenza vaccine, flu; Guillain-Barré Syndrome, GBS; Attorney fees and costs minor child, JUAN SANCHEZ 3/13/2012
Stipulation; influenza (flu) vaccine; syncope; allergic reaction; orthostatic hypotension JESSICA JONES 03/12/2012
Stipulation; influenza (flu) vaccine ; Guillain-Barre Syndrome (GBS); attorneys’ fees and costs; award in the amount to which respondent does not object MERRELL S. McILWAIN 03/08/2012
Stipulation; influenza vaccine; Guillain Barre Syndrome MOSCA FLINT 03/02/2012
Damages Decision Based on Stipulation; Flu Vaccine; ADEM; Death ; Attorneys?Fees & Costs Decision Based on Stipulation Estate of, SEAN WEISSE 02/29/2012
Stipulation; Guillain-Barré Syndrome, GBS; Influenza vaccine, flu; Tetanus-diphtheria-acellular pertussis, Tdap MEGAN BAUER 02/29/2012
Proffer; Influenza vaccine, flu; Acute disseminated encephalomyelitis, ADEM THURMAN DANIELS 02/16/2012
Damages Decision Based on Stipulation; Flu Vaccine ; GBS DAVID JOSEPH POLCIK 02/02/2012
Stipulation; Influenza (flu) vaccine ; Guillian-Barre Syndrome (GBS) DAN SMITH 02/02/2012
Damages Decision Based on Stipulation; Flu Vaccine; Leukocytoclastic Vasculitis; Urticaria Parents and Natural Guardians of minor DENNIS J. FLANAGAN 01/30/2012
Stipulation; Influenza vaccine, flu; Guillain-Barré Syndrome, GBS DOMINGO MARTINEZ 01/30/2012
Decision by stipulation; Influenza Vaccine ; Guillain Barre Syndrome JOHN HICKMAN, January 27, 2012
Damages Decision Based on Stipulation; Flu Vaccine; GB TAMY T. NGUYEN January 27, 2012
Decision by stipulation; Influenza Vaccine ; Guillain Barre Syndrome CHRISTOPHER COALE, January 24, 2012
Flu vaccine; cytokine storm; death of 82-year-old man six days after vaccination; sepsis/systemic inflammatory response; Zatuchni; pain and suffering of decedent pre-filing of petition Estate of EDGAR BRAGG, January 18, 2012
Decision by Stipulation; Influenza, Tdap and MMR; Shoulder Pain; Numbness and Dysfunction WALTER GROSH, January 17, 2012
Decision by Stipulation; Influenza, Tdap and Menningococcal Vaccines; Transverse Myelitis Peter Cieszewski . January 13, 2012
Stipulation; influenza (flu) vaccine; Guillain-Barre Syndrome (GBS); death Estate of CHARLES JAMES BUSALACCHI, January 10, 2012
Stipulation; influenza (flu) vaccine ; pneumococcal conjugate vaccine (PCV); Guillain-Barre Syndrome (GBS FRUTO SOTO, January 10, 2012
Stipulation; influenza (flu) vaccine ; right deltoid cellulitis; serum sickness; connective tissue disorder; rheumatoid arthritis; Sjogren’s syndrome; autoimmune hepatitis; fibromyalgia KARON MERRILL January 10, 2012
Stipulation; Influenza; GBS death Estate of GUADALUPE G. GONZALEZ, January 9, 2012
Damages Decision Based on Stipulation; Flu Vaccine; GBS; Attorney抯 Fees and Costs Decision Based on Stipulation GUILLERMINA RAMIREZ, January 5, 2012
Stipulation; influenza vaccine; Guillain-Barre Syndrome death Estate of REX KIMBELL January 5, 2012
Flu Vaccine ; Guillain-Barre-Syndrome (GBS);Stipulation of damages; Award and attorney’s fees MARGARET CLANT January 5, 2012)
Stipulation; trivalent influenza vaccination ; acute-disseminated encephalomyelitis JUANITA SPARROW January 4, 2012
Here is info from Cochrane reviews for healthy children:
From Cochrane Reviews The Cochrane Library
Vaccines for preventing influenza in healthy children
Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E, August 15, 2012
Children (< 16 years old) and the elderly (above 65 years old) are the two age groups that appear to have the most complications following an influenza infection. Influenza has a viral origin and often results in an acute respiratory illness affecting the lower or upper parts of the respiratory tract, or both. Viruses are mainly of two subtypes (A or B) and spread periodically during the autumn-winter months. However, many other viruses can also cause respiratory tract illnesses.
Diffusion and severity of the disease could be very different during different epidemics. Efforts to contain epidemic diffusion rely mainly on widespread vaccination. Recent policy from several internationally-recognised institutions, recommend immunisation of healthy children between 6 and 23 months of age (together with their contacts) as a public health measure.
The review authors found that in children aged from two years, nasal spray vaccines made from weakened influenza viruses were better at preventing illness caused by the influenza virus than injected vaccines made from the killed virus. Neither type was particularly good at preventing ‘flu-like illness’ caused by other types of viruses.
In children under the age of two, the efficacy of inactivated vaccine was similar to placebo. It was not possible to analyze the safety of vaccines from the studies due to the lack of standardization in the information given, but very little information was found on the safety of inactivated vaccines, the most commonly used vaccine in young children.
We included 75 studies with about 300,000 observations. We included 17 RCTs, 19 cohort studies and 11 case-control studies in the analysis of vaccine efficacy and effectiveness. Evidence from RCTs shows that six children under the age of six need to be vaccinated with live attenuated vaccine to prevent one case of influenza (infection and symptoms). We could find no usable data for those aged two years or younger.
Inactivated vaccines in children aged two years or younger are not significantly more efficacious than placebo. Twenty-eight children over the age of six need to be vaccinated to prevent one case of influenza (infection and symptoms). Eight need to be vaccinated to prevent one case of influenza-like-illness (ILI). We could find no evidence of effect on secondary cases, lower respiratory tract disease, drug prescriptions, otitis media and its consequences and socioeconomic impact. We found weak single-study evidence of effect on school absenteeism by children and caring parents from work. Variability in study design and presentation of data was such that a meta-analysis of safety outcome data was not feasible. Extensive evidence of reporting bias of safety outcomes from trials of live attenuated influenza vaccines (LAIVs) impeded meaningful analysis. One specific brand of monovalent pandemic vaccine is associated with cataplexy and narcolepsy in children and there is sparse evidence of serious harms (such as febrile convulsions) in specific situations.
Influenza vaccines are efficacious in preventing cases of influenza in children older than two years of age, but little evidence is available for children younger than two years of age. There was a difference between vaccine efficacy and effectiveness, partly due to differing datasets, settings and viral circulation patterns. No safety comparisons could be carried out, emphasizing the need for standardization of methods and presentation of vaccine safety data in future studies. In specific cases, influenza vaccines were associated with serious harms such as narcolepsy and febrile convulsions.
It was surprising to find only one study of inactivated vaccine in children under two years, given current recommendations to vaccinate healthy children from six months of age in the USA, Canada, parts of Europe and Australia. If immunization in children is to be recommended as a public health policy, large-scale studies assessing important outcomes, and directly comparing vaccine types are urgently required. The degree of scrutiny needed to identify all global cases of potential harms is beyond the resources of this review.
Here is info from Cochrane on healthy adults:
Information is from – Cochrane Reviews are systematic reviews of primary research in human health care and health policy, and are internationally recognized as the highest standard in evidence-based health care. They investigate the effects of interventions for prevention, treatment and rehabilitation. They also assess the accuracy of a diagnostic test for a given condition in a specific patient group and setting. They are published online in The Cochrane Library.
Vaccines to prevent influenza in healthy adults
July 7, 2010
Over 200 viruses cause influenza and influenza-like illness which produce the same symptoms (fever, headache, aches and pains, cough and runny noses). Without laboratory tests, doctors cannot tell the two illnesses apart. Both last for days and rarely lead to death or serious illness. At best, vaccines might be effective against only influenza A and B, which represent about 10% of all circulating viruses. Each year, the World Health Organization recommends which viral strains should be included in vaccinations for the forthcoming season. Authors of this review assessed all trials that compared vaccinated people with unvaccinated people. The combined results of these trials showed that under ideal conditions (vaccine completely matching circulating viral configuration) 33 healthy adults need to be vaccinated to avoid one set of influenza symptoms. In average conditions (partially matching vaccine) 100 people need to be vaccinated to avoid one set of influenza symptoms. Vaccine use did not affect the number of people hospitalized or working days lost but caused one case of Guillian-Barré syndrome (a major neurological condition leading to paralysis) for every one million vaccinations. Fifteen of the 36trials were funded by vaccine companies and four had no funding declaration. Our results may be an optimistic estimate because company-sponsored influenza vaccines trials tend to produce results favorable to their products and some of the evidence comes from trials carried out in ideal viral circulation and matching conditions and because the harms evidence base is limited..
We included 50 reports. Forty (59 sub-studies) were clinical trials of over 70,000 people. Eight were comparative non-RCTs and assessed serious harms. Two were reports of harms which could not be introduced in the data analysis. In the relatively uncommon circumstance of vaccine matching the viral circulating strain and high circulation, 4% of unvaccinated people versus 1% of vaccinated people developed influenza symptoms (risk difference (RD) 3%, . The corresponding figures for poor vaccine matching were 2% and 1%. These differences were not likely to be due to chance. Vaccination had a modest effect on time off work and had no effect on hospital admissions or complication rates. Inactivated vaccines caused local harms and an estimated 1.6 additional cases of Guillain-Barré Syndrome per million vaccinations. The harms evidence base is limited.
Influenza vaccines have a modest effect in reducing influenza symptoms and working days lost. There is no evidence that they affect complications, such as pneumonia, or transmission.
This review includes 15 out of 36 trials funded by industry (four had no funding declaration). An earlier systematic review of 274 influenza vaccine studies published up to 2007 found industry funded studies were published in more prestigious journals and cited more than other studies independently from methodological quality and size. Studies funded from public sources were significantly less likely to report conclusions favorable to the vaccines. The review showed that reliable evidence on influenza vaccines is thin but there is evidence of widespread manipulation of conclusions and spurious notoriety of the studies. The content and conclusions of this review should be interpreted in light of this finding.